Session 2P
Innovation in Surgical Techniques and in the Diagnosis and Treatment of Oncologic Diseases
3:30 PM to 5:00 PM | Moderated by Amy Cizik
- Presenter
-
- Kevin Ma, Senior, Pre-Major Mary Gates Scholar
- Mentors
-
- David Flum,
- Sarah Lawrence, , Surgical Outcomes Research Center
- Session
-
- 3:30 PM to 5:00 PM
The adverse effects of perioperative hypothermia have been well established. However, many anesthesiologists often fail to document the body temperature of patients during the perioperative period. One of the goals of the Surgical Care and Outcomes Assessment Program (SCOAP), a clinical data-sharing quality improvement program focusing on surgical healthcare delivery and outcomes and subscribed to by 55+ hospitals in Washington State, is to increase proper documentation of perioperative body temperature (PBT). We assessed whether enrollment in SCOAP had any effect on PBT documentation. PBT was abstracted from the anesthesia records of all patients who underwent SCOAP-eligible procedures at one newly enrolled SCOAP hospital. As feedback from SCOAP is provided quarterly, we then compared the rates of proper documentation during the first and second quarters following enrollment. During the first quarter of SCOAP participation, PBT was documented in 51% of SCOAP eligible procedures, while during the second quarter, PBT documentation had increased to 65% of SCOAP eligible procedures. These data suggest that enrollment in SCOAP has a positive effect on proper PBT documentation, and subsequent quarters should be monitored to ascertain whether continued enrollment in SCOAP may result in further improvement.
- Presenter
-
- Sara Ann Huberty, Junior, Environmental Science & Resource Management (Wildlife Conservation)
- Mentor
-
- Allen Gabriel,
- Session
-
- 3:30 PM to 5:00 PM
Management of complicated wounds pose a continual challenge to health care providers, particularly in patients with associated risk factors and co-morbidities. Negative pressure wound therapy (NPWT) is becoming the standard of care in open wounds. This study evaluated the role of NPWT in closed incisions in patients with high risk factors for wound breakdown. 15 consecutive patients were evaluated in this pilot study. VAC therapy (KCI) was utilized as our NPWT of choice and was applied in the operating room to clean, closed surgical wounds. GranuFoam Silver dressing (KCI) was applied to all closed wounds. The therapy was initiated at 125mmHG below ambient pressure in a continuous mode for 3-5 days. Patient inclusion criteria included a minimum of one of the risk factors: BMI >35, diabetes mellitus, peripheral vascular disease, smoking, history of radiation, steroid use, and malnutrition measured by albumin and prealbumin. Mean follow-up was 9 months. All patients completed their treatment successfully. Surgical incisions ranged from abdominal, chest and lower extremity incisions. There were no returns to the operating rooms and no wound breakdowns. No other complications were seen in our pilot study. These results are suggestive of NPWT role over incisional use in high-risk patients. Clearly randomized trials need to address this in the near future; however, we recommend its use on high-risk patients who are undergoing elective or emergent procedures to minimize wound breakdown and improve healing.
- Presenter
-
- Ryan Ruey-En (Ryan) Sun, Senior, Neuroscience Mary Gates Scholar
- Mentor
-
- Savannah Partridge,
- Session
-
- 3:30 PM to 5:00 PM
Magnetic resonance imaging (MRI) has proven to be a highly sensitive method for identifying breast cancer and determining the location and extent of tumor in the breast. Diffusion-weighted imaging (DWI), a specialized form of MRI that characterizes tissue microstructure in vivo based on the random microscopic motion of water molecules, has shown promise for early detection of treatment response in tumors. The apparent diffusion coefficient (ADC), a quantitative parameter calculated from DWI, reflects the degree of water mobility in the extracellular space and provides a measure of tissue cellularity. Previous studies have found that the ADC in tumors increases in response to chemotherapy earlier than the manifestation of detectable changes in morphology or vascularity found through conventional imaging techniques. This increase in ADC is likely due to a loss of cell membrane integrity and increased fractional volume of extracellular space, and may be a valuable predictor of treatment efficacy. In this study, we measured tumor ADC in breast cancer patients who underwent serial breast DWIs during preoperative chemotherapy. Changes in tumor ADC throughout treatment were compared with the pathological findings of the removed breast tissue to investigate the value of ADC in predicting treatment response. Our preliminary data indicates that the change in minimum ADC at mid-treatment was significantly different between pathologic response groups. This suggests that minimum ADC may represent the most viable, cellular area of the tumor and might better reflect tumor response to treatment. Early prediction of treatment outcome would not only allow the patients to be put on regimens that are more likely to treat the disease, it would also prevent them from undergoing ineffective treatments that cause unnecessary toxicity, physical distress, and therapeutic delay.
- Presenter
-
- Lola Mudgistratova, Junior, Sociology
- Mentors
-
- Paul Nghiem,
- Kotaro Nagase,
- Session
-
- 3:30 PM to 5:00 PM
Merkel cell carcinoma (MCC) is a rare but aggressive form of skin cancer that is associated with a recently discovered polyomavirus, Merkel cell polyomavirus (MCPyV). The incidence rate of MCC is increasing, but current treatments and methods of detecting disease recurrence/metastasis are limited; tests are expensive, unspecific, and insensitive. Consequently, more than one third of MCC patients die from this disease. However, preliminary studies have shown that patients produce immune system proteins called antibodies against MCPyV T-antigen, a tumorigenic viral protein, and that the level of these antibodies changes with disease status. A higher serum concentration of anti-T-Antigen antibodies correlates with disease recurrence or metastasis. Therefore, these antibodies can be used to track disease progression. This study will validate this hypothesis through an enzyme-linked immunosorbent assay (ELISA) that measures the level of antibodies in patient serum. In the laboratory, viral T-antigen and non-antigenic control proteins were grown up using E.coli. Those purified proteins were then attached to the bottom of the wells of a 96-well ELISA plate. A blocking buffer was used to minimize the binding of unspecific antibodies, and varying dilutions of patient serum were applied to the wells to allow the binding of T-antigen-specific antibodies. Bound antibodies were visualized using a secondary antibody conjugated with a color-producing enzyme. Promising preliminary results indicated that we are able to distinguish between patients with high, intermediate, and low/negative levels of anti-T-antigen antibodies. Future work will continue to optimize the stability and reproducibility of the assay. In particular, more work will be done to reduce the background noise and maximize the signal. This assay may be a useful and cost effective clinical tool for tracking MCC.
- Presenter
-
- Neela Ramanujam, Senior, Biology (Molecular, Cellular & Developmental) Mary Gates Scholar
- Mentor
-
- Alanna Ruddell,
- Session
-
- 3:30 PM to 5:00 PM
The lymphatic system is essential to fluid and cell transport, immune function, and tumor metastasis. Lymph drains from body extremities into lymph nodes, via lymphatic vessels, to present antigens to lymphocytes. This can result in an immune response. The existence of tumor cells in lymph nodes is a sign that cellular metastasis has occurred from the primary tumor. I am studying lymphangiogenesis, a process in which lymphatic vessels and sinuses grow and dilate in response to antigens or tumors, thus increasing the lymph flow and capacity to transport tumor cells in lymph nodes. Recently an antibody, 10.1.1, has been discovered to recognize an antigen that is selectively and highly expressed in lymphatic endothelium. The 10.1.1 antibody specifically induces lymph node lymphangiogenesis. This binding also induces proliferation of an unknown cell type in the lymph node. In comparison to the 10.1.1 antibody, injecting a nonspecific antibody control has no effect on lymphatic sinus growth. I am therefore studying how the 10.1.1 antibody rapidly induces lymphatic sinus growth, as well as what cell types contribute to making the new sinuses. I am using the technique of immunostaining to study the effects of the 10.1.1 antibody. By taking a frozen slice of lymphatic tissue and staining it with various antibodies to detect proliferating cells and their cell type, I can identify the specific kinds of cells that are forming into lymphatic sinuses. An understanding of how these lymphatic sinuses grow could help generate therapeutic strategies for manipulation of the lymphatic or immune responses. By inhibiting sinus growth and thus limiting lymph flow, it could be possible to prevent the metastasis of cancer.
The University of Washington is committed to providing access and accommodation in its services, programs, and activities. To make a request connected to a disability or health condition contact the Office of Undergraduate Research at undergradresearch@uw.edu or the Disability Services Office at least ten days in advance.